イブプロフェンAPIの世界市場

イブプロフェンAPIの世界市場は2030年までに8億780万米ドルに達する見込み

2024年に7億6,550万米ドルと推定されるイブプロフェンAPIの世界市場は、2024～2030年の分析期間にCAGR 0.9%で成長し、2030年には8億780万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである関節炎アプリケーションは、CAGR 1.4%を記録し、分析期間終了時には3億9,200万米ドルに達すると予測されます。頭痛アプリケーション分野の成長率は、分析期間中CAGR 0.6％と推定されます。

米国市場は2億120万米ドルと推定、中国はCAGR 0.7％で成長予測

米国のイブプロフェンAPI市場は、2024年に2億120万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億2,960万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは0.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8％と0.7％と予測されています。欧州では、ドイツがCAGR約0.2%で成長すると予測されています。

世界のイブプロフェンAPI市場- 主要動向と促進要因のまとめ

各業界におけるイブプロフェンAPI需要の原動力は？

イブプロフェンAPI市場は、その有用性と消費量を増加させる医療、産業、人口統計学的要因の組み合わせに後押しされ、拡大を続けています。新興国を中心とした世界のヘルスケア支出の増加は、非ステロイド性抗炎症薬（NSAIDs）の需要を大幅に押し上げており、中でもイブプロフェンはその有効性と安全性が証明されているため、主要な競合薬となっています。北米、欧州、アジアの一部を中心に、世界の高齢化が慢性疼痛や炎症関連疾患の急増に寄与しており、イブプロフェンをベースとした治療薬に大きく依存しています。さらに、製薬業界が十分なサービスを受けていない地域での必須医薬品へのアクセスを増やすことに注力していることが、定番医薬品成分としてのイブプロフェンAPIの重要性を高めています。医療用途にとどまらず、イブプロフェンは動物の疼痛や炎症の管理に使用される獣医学分野でも需要が高まっており、市場基盤はさらに多様化しています。

技術革新は市場をどのように形成しているか？

イブプロフェン市場は、医薬品製造技術の進歩により、その製造手法に革命が起きています。自動化とリアルタイム監視システムに支えられた連続製造プロセスは、イブプロフェン製造の効率性、拡張性、品質の一貫性を大幅に向上させました。こうした技術革新により、製造コストの削減とエラーの最小化が実現し、厳格な規制基準の遵守が保証されました。もうひとつの注目すべき動向は、グリーンケミストリーの原則を製造工程に取り入れることです。メーカー各社は、世界の持続可能性の目標に沿うため、水の効率的な合成、溶媒のリサイクル、生分解性原料の使用など、環境にやさしい方法を採用しています。さらに、研究開発の努力により、バイオアベイラビリティが改善され、副作用が軽減されたイブプロフェンの革新的な製剤が開発され、健康志向の高まる消費者層に対応しつつあります。こうした進歩は、大手企業の競争力を維持すると同時に、新規参入企業が持続可能な慣行を採用して市場シェアを獲得する道を開く上で極めて重要です。

イブプロフェンAPI市場を定義する地域・部門動向とは？

イブプロフェンAPI市場の地域力学を見ると、生産拠点と消費拠点が明確に分かれていることがわかる。インドと中国は、政府の優遇措置、豊富な原材料、熟練した労働力に支えられ、この地域を支配しています。これらの国々はまた、コスト面での優位性を生かして、北米、欧州、その他の消費量の多い市場に原薬を供給しています。一方、北米や欧州などの先進地域は、高度なヘルスケアシステムと、関節炎、心血管疾患、糖尿病などの慢性疾患の蔓延が原動力となって、高品質のイブプロフェン原薬の需要を牽引しています。さらに、eコマースセクターの拡大により、特に消費者が迅速で便利な医薬品へのアクセスを求める都市部において、イブプロフェンをベースとした製品の店頭販売の成長が加速しています。新興経済諸国では農村部のヘルスケア・インフラが発展しており、イブプロフェンAPIの需要はこれまで未開拓だった市場に浸透していくと予想されます。

イブプロフェンAPI市場の成長を促進する要因は？

イブプロフェンAPI市場の成長は、テクノロジーの進歩、最終用途、消費者行動の変化に直結するいくつかの要因によって牽引されています。最も重要な原動力の一つは、高齢化と座りっぱなしのライフスタイルの製品別である、炎症や痛みに関連する症状の有病率の増加です。これに加え、世界的に外科手術の発生率が上昇しており、術後の疼痛管理ソリューションが必要とされることが多いため、イブプロフェンの需要がさらに高まっています。プロセスの自動化や品質モニタリングなど、医薬品製造の技術的進歩により生産が合理化され、高品位原薬の安定供給が保証されています。さらに、製薬業界では研究開発投資が活発化しており、作用発現の速さや胃腸の副作用の軽減など、特定の医療ニーズに対応した新しいイブプロフェン製剤が開発されています。消費者側では、セルフメディケーションや市販薬購入の動向が急増しており、一般的な病気に対して費用対効果が高く、すぐに入手できる解決策を求める情報通の消費者に支えられています。オンライン薬局やヘルスケア流通チャネルのデジタル化は、アクセスをさらに簡素化し、市場の裾野を広げています。これらの要因が相互に関連し合うことで、進化するヘルスケア需要への対応においてイブプロフェンAPIの重要性が世界的に高まっています。

セグメント

用途（関節炎用途、頭痛用途、その他用途）、最終用途（製薬・バイオファーマ企業最終用途、臨床研究機関・CMO最終用途）

調査対象企業の例（注目の41社）

• Abbott Laboratories, Inc.
• Anantco Enterprises Pvt. Ltd.
• BASF SE
• Dr. Reddy's Laboratories Ltd.
• Granules India Limited.
• Iol Chemicals & Pharmaceutical
• LGM Pharma
• Octavius Pharma Pvt. Ltd.
• Pfizer, Inc.
• Rochem International Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Ibuprofen API Market to Reach US$807.8 Million by 2030

The global market for Ibuprofen API estimated at US$765.5 Million in the year 2024, is expected to reach US$807.8 Million by 2030, growing at a CAGR of 0.9% over the analysis period 2024-2030. Arthritis Application, one of the segments analyzed in the report, is expected to record a 1.4% CAGR and reach US$392.0 Million by the end of the analysis period. Growth in the Headache Application segment is estimated at 0.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$201.2 Million While China is Forecast to Grow at 0.7% CAGR

The Ibuprofen API market in the U.S. is estimated at US$201.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$129.6 Million by the year 2030 trailing a CAGR of 0.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 0.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.2% CAGR.

Global Ibuprofen API Market - Key Trends & Drivers Summarized

What Drives the Demand for Ibuprofen API Across Industries?

The ibuprofen API market continues to expand, fueled by a combination of medical, industrial, and demographic factors that collectively increase its utility and consumption. Rising global healthcare expenditures, especially in emerging economies, have significantly boosted the demand for non-steroidal anti-inflammatory drugs (NSAIDs), with ibuprofen being a key contender due to its proven efficacy and safety profile. The aging population worldwide, particularly in North America, Europe, and parts of Asia, is contributing to a surge in chronic pain and inflammation-related disorders, which rely heavily on ibuprofen-based therapies. Furthermore, the pharmaceutical industry’s focus on increasing access to essential medicines in underserved regions has elevated the importance of ibuprofen API as a staple drug ingredient. Beyond medical applications, the demand is also rising in veterinary medicine, where ibuprofen is used in managing pain and inflammation in animals, further diversifying its market base.

How Are Technological Innovations Shaping the Market?

The ibuprofen API market has witnessed a revolution in its production methodologies, driven by advancements in pharmaceutical manufacturing technologies. Continuous manufacturing processes, supported by automation and real-time monitoring systems, have significantly enhanced the efficiency, scalability, and quality consistency of ibuprofen production. These innovations have reduced production costs and minimized errors, ensuring compliance with stringent regulatory standards. Another notable trend is the integration of green chemistry principles into production processes. Manufacturers are adopting environmentally friendly methods, such as water-efficient synthesis, solvent recycling, and the use of biodegradable raw materials, to align with global sustainability goals. Moreover, research and development efforts are unlocking innovative formulations of ibuprofen with improved bioavailability and reduced side effects, catering to an increasingly health-conscious consumer base. These advancements are critical in maintaining the competitive edge of leading players while paving the way for new entrants to adopt sustainable practices and gain market share.

What Regional and Sectoral Trends Define the Ibuprofen API Market?

The regional dynamics of the ibuprofen API market reveal a clear divide between production and consumption centers, with Asia-Pacific emerging as the leading producer due to its robust pharmaceutical manufacturing infrastructure. India and China dominate this landscape, supported by government incentives, abundant raw materials, and skilled labor forces. These countries are also capitalizing on their cost advantages to supply APIs to North America, Europe, and other high-consumption markets. On the other hand, developed regions such as North America and Europe drive the demand for high-quality ibuprofen APIs, fueled by advanced healthcare systems and the widespread prevalence of chronic diseases like arthritis, cardiovascular conditions, and diabetes. Additionally, the expansion of the e-commerce sector has accelerated the growth of over-the-counter sales of ibuprofen-based products, particularly in urban areas where consumers demand quick and convenient access to medications. As rural healthcare infrastructure develops in emerging economies, the demand for ibuprofen API is expected to penetrate previously untapped markets.

What Factors Are Driving the Growth of the Ibuprofen API Market?

The growth in the Ibuprofen API market is driven by several factors directly linked to advancements in technology, end-use applications, and shifting consumer behavior. One of the most critical drivers is the increasing prevalence of inflammatory and pain-related conditions, a byproduct of aging populations and sedentary lifestyles. This is compounded by the rising incidence of surgical procedures globally, which often necessitate post-operative pain management solutions, further boosting ibuprofen demand. Technological advancements in pharmaceutical manufacturing, including process automation and quality monitoring, have streamlined production, ensuring the consistent availability of high-grade APIs. Additionally, the pharmaceutical industry has witnessed an uptick in R&D investments, leading to novel ibuprofen formulations tailored to address specific medical needs such as faster onset of action and reduced gastrointestinal side effects. On the consumer front, the trend toward self-medication and over-the-counter drug purchases has surged, supported by better-informed individuals seeking cost-effective and readily available solutions for common ailments. Online pharmacies and the digitization of healthcare distribution channels have further simplified access, broadening the market’s reach. Altogether, these interconnected factors underscore the growing prominence of ibuprofen API in addressing evolving healthcare demands globally.

SCOPE OF STUDY:

The report analyzes the Ibuprofen API market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Arthritis Application, Headache Application, Other Applications); End-Use (Pharma & Biopharma Companies End-Use, Clinical Research Organizations & CMOs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

• Abbott Laboratories, Inc.
• Anantco Enterprises Pvt. Ltd.
• BASF SE
• Dr. Reddy's Laboratories Ltd.
• Granules India Limited.
• Iol Chemicals & Pharmaceutical
• LGM Pharma
• Octavius Pharma Pvt. Ltd.
• Pfizer, Inc.
• Rochem International Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Economic Frontiers: Trends, Trials & Transformations
  • Ibuprofen API - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Over-the-Counter (OTC) Pain Relief Fuels Growth in Ibuprofen API Production
  • Increased Prevalence of Chronic Pain Conditions Drives Demand for Ibuprofen APIs
  • Expansion of Generic Drug Manufacturing Strengthens Market for Ibuprofen APIs
  • Focus on Affordable Healthcare Fuels Growth in Ibuprofen API Demand Globally
  • Advancements in API Manufacturing Processes Propel Cost-Efficiency and Market Growth
  • Stringent Quality Regulations Highlight the Need for Compliance in Ibuprofen API Production
  • Focus on Sustainable and Green Chemistry Drives Innovation in API Manufacturing
  • Rising Global Pharmaceutical Outsourcing Creates Opportunities for Ibuprofen API Producers
  • Growth in Emerging Markets Spurs Demand for Cost-Effective Ibuprofen APIs
  • Focus on Combating Counterfeit APIs Strengthens Quality Standards in Ibuprofen Production
  • Increased Adoption of Pain Management Therapies Expands Ibuprofen API Applications
  • Focus on Fast-Acting and Extended-Release Formulations Enhances Demand for High-Quality APIs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Ibuprofen API Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Ibuprofen API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Ibuprofen API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Arthritis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Headache Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Headache Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Pharma & Biopharma Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Clinical Research Organizations & CMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Clinical Research Organizations & CMOs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Ibuprofen API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Ibuprofen API by Application - Arthritis Application, Headache Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 15: USA 6-Year Perspective for Ibuprofen API by Application - Percentage Breakdown of Value Sales for Arthritis Application, Headache Application and Other Applications for the Years 2025 & 2030
  • TABLE 16: USA Recent Past, Current & Future Analysis for Ibuprofen API by End-Use - Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 17: USA 6-Year Perspective for Ibuprofen API by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use for the Years 2025 & 2030
• CANADA
  • TABLE 18: Canada Recent Past, Current & Future Analysis for Ibuprofen API by Application - Arthritis Application, Headache Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 19: Canada 6-Year Perspective for Ibuprofen API by Application - Percentage Breakdown of Value Sales for Arthritis Application, Headache Application and Other Applications for the Years 2025 & 2030
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Ibuprofen API by End-Use - Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 21: Canada 6-Year Perspective for Ibuprofen API by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use for the Years 2025 & 2030
• JAPAN
  • Ibuprofen API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 22: Japan Recent Past, Current & Future Analysis for Ibuprofen API by Application - Arthritis Application, Headache Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 23: Japan 6-Year Perspective for Ibuprofen API by Application - Percentage Breakdown of Value Sales for Arthritis Application, Headache Application and Other Applications for the Years 2025 & 2030
  • TABLE 24: Japan Recent Past, Current & Future Analysis for Ibuprofen API by End-Use - Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 25: Japan 6-Year Perspective for Ibuprofen API by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use for the Years 2025 & 2030
• CHINA
  • Ibuprofen API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 26: China Recent Past, Current & Future Analysis for Ibuprofen API by Application - Arthritis Application, Headache Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: China 6-Year Perspective for Ibuprofen API by Application - Percentage Breakdown of Value Sales for Arthritis Application, Headache Application and Other Applications for the Years 2025 & 2030
  • TABLE 28: China Recent Past, Current & Future Analysis for Ibuprofen API by End-Use - Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 29: China 6-Year Perspective for Ibuprofen API by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use for the Years 2025 & 2030
• EUROPE
  • Ibuprofen API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 30: Europe Recent Past, Current & Future Analysis for Ibuprofen API by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 31: Europe 6-Year Perspective for Ibuprofen API by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Ibuprofen API by Application - Arthritis Application, Headache Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Europe 6-Year Perspective for Ibuprofen API by Application - Percentage Breakdown of Value Sales for Arthritis Application, Headache Application and Other Applications for the Years 2025 & 2030
  • TABLE 34: Europe Recent Past, Current & Future Analysis for Ibuprofen API by End-Use - Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Europe 6-Year Perspective for Ibuprofen API by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use for the Years 2025 & 2030
• FRANCE
  • Ibuprofen API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 36: France Recent Past, Current & Future Analysis for Ibuprofen API by Application - Arthritis Application, Headache Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 37: France 6-Year Perspective for Ibuprofen API by Application - Percentage Breakdown of Value Sales for Arthritis Application, Headache Application and Other Applications for the Years 2025 & 2030
  • TABLE 38: France Recent Past, Current & Future Analysis for Ibuprofen API by End-Use - Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: France 6-Year Perspective for Ibuprofen API by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use for the Years 2025 & 2030
• GERMANY
  • Ibuprofen API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 40: Germany Recent Past, Current & Future Analysis for Ibuprofen API by Application - Arthritis Application, Headache Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Germany 6-Year Perspective for Ibuprofen API by Application - Percentage Breakdown of Value Sales for Arthritis Application, Headache Application and Other Applications for the Years 2025 & 2030
  • TABLE 42: Germany Recent Past, Current & Future Analysis for Ibuprofen API by End-Use - Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Germany 6-Year Perspective for Ibuprofen API by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use for the Years 2025 & 2030
• ITALY
  • TABLE 44: Italy Recent Past, Current & Future Analysis for Ibuprofen API by Application - Arthritis Application, Headache Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Italy 6-Year Perspective for Ibuprofen API by Application - Percentage Breakdown of Value Sales for Arthritis Application, Headache Application and Other Applications for the Years 2025 & 2030
  • TABLE 46: Italy Recent Past, Current & Future Analysis for Ibuprofen API by End-Use - Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Italy 6-Year Perspective for Ibuprofen API by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use for the Years 2025 & 2030
• UNITED KINGDOM
  • Ibuprofen API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 48: UK Recent Past, Current & Future Analysis for Ibuprofen API by Application - Arthritis Application, Headache Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 49: UK 6-Year Perspective for Ibuprofen API by Application - Percentage Breakdown of Value Sales for Arthritis Application, Headache Application and Other Applications for the Years 2025 & 2030
  • TABLE 50: UK Recent Past, Current & Future Analysis for Ibuprofen API by End-Use - Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: UK 6-Year Perspective for Ibuprofen API by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Ibuprofen API by Application - Arthritis Application, Headache Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Rest of Europe 6-Year Perspective for Ibuprofen API by Application - Percentage Breakdown of Value Sales for Arthritis Application, Headache Application and Other Applications for the Years 2025 & 2030
  • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Ibuprofen API by End-Use - Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Rest of Europe 6-Year Perspective for Ibuprofen API by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use for the Years 2025 & 2030
• ASIA-PACIFIC
  • Ibuprofen API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Ibuprofen API by Application - Arthritis Application, Headache Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Asia-Pacific 6-Year Perspective for Ibuprofen API by Application - Percentage Breakdown of Value Sales for Arthritis Application, Headache Application and Other Applications for the Years 2025 & 2030
  • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Ibuprofen API by End-Use - Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Asia-Pacific 6-Year Perspective for Ibuprofen API by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 60: Rest of World Recent Past, Current & Future Analysis for Ibuprofen API by Application - Arthritis Application, Headache Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Rest of World 6-Year Perspective for Ibuprofen API by Application - Percentage Breakdown of Value Sales for Arthritis Application, Headache Application and Other Applications for the Years 2025 & 2030
  • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Ibuprofen API by End-Use - Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Rest of World 6-Year Perspective for Ibuprofen API by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use and Clinical Research Organizations & CMOs End-Use for the Years 2025 & 2030

IV. COMPETITION